2024 Retrospective: Clinical Efficacy

As we close out 2024, it is critical to review the strides made in the clinical understanding of natural alga-derived supplements, particularly those rich in stereoisomers like 9-cis beta-carotene.

This year saw three major multi-center trials conclude, providing robust data that shifts our understanding from theoretical biochemistry to proven human outcomes.

Trial A: Bioavailability Mapping

The largest trial of the year mapped the plasma kinetics of synthetic all-trans beta-carotene against natural Dunaliella bardawil extract.

• Result: The natural extract showed a biphasic absorption curve, leading to sustained plasma presence that was 2.5x longer than the synthetic baseline.

Trial B: Visual Acuity in Aging Populations

Focusing on subjects over 65, this study measured contrast sensitivity and dark adaptation over 6 months.

• Result: A statistically significant improvement in recovery time following a photostress test, correlating with increased macular pigment optical density (MPOD).

Trial C: Safety and Tolerability

A crucial 12-month longitudinal study confirmed that high-level supplementation of the natural stereoisomer mix does not suppress the absorption of other fat-soluble vitamins (A, D, E, K).

Looking Forward to 2025

The data gathered this year paves the way for more targeted applications. We expect 2025 to herald new investigations into how 9-cis beta-carotene interacts with specific genetic profiles regarding lipid metabolism.